Last updated: 2026-10-16 02:57:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
DaVita Inc. (DVA) operates in the SERVICES-MISC HEALTH & ALLIED SERVICES, NEC sector and is listed on NYSE. The stock is currently priced at $189,14, with a market capitalisation of $11,62B and a P/E ratio of 13,60. Over the past 52 weeks, its price has ranged from $101,00 to $247,49. This page covers its latest market performance, valuation, price trends and company information.
$11,62B | |
$187,11 | |
$247,49 | |
$10,22 | |
$180,70 | |
239,57K | |
757,89K | |
13,60 | |
$247,49 | |
$101,00 | |
-- | |
-- |
DaVita Inc. (DVA) last closed at $180,70 as of 2026-10-15 23:52:00, unchanged from the previous close of $180,70.
During the latest regular trading session, DVA traded between $10,22 and $247,49, with a volume of 239,57K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, DaVita Inc. (DVA) moved from $180,40 to $189,14, representing a gain of 4,84% ($8,74).
The stock traded between $175,41 and $189,15 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 486,91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 60,2%
DVA is currently trading at $189,14, placing it 60,2% of the way from its 52-week low of $101,00 to its 52-week high of $247,49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
| Industry | SERVICES-MISC HEALTH & ALLIED SERVICES, NEC |
| Employees | 78000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of DaVita Inc. (DVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.